Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B

Journal of Infection

Volumn 67, Issue 4, 2013, Pages 322-328

  Coppola, Nicola ^a   Tonziello, Gilda ^a   Colombatto, Piero ^b   Pisaturo, Mariantonietta ^a   Messina, Vincenzo ^c   Moriconi, Francesco ^b   Alessio, Loredana ^a   Sagnelli, Caterina ^d   Cavallone, Daniela ^b   Brunetto, Maurizia ^b   Sagnelli, Evangelista ^a,c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Hepatology Unit   (Italy)

^c Infectious Diseases   (Italy)

^d SecondUniversity of Naples ^*  (Italy)

Author keywords

Acute hepatitis B; Lamivudine; Mutant HBV strains; Resistance to nucleos(t)ide analogues; RtM204I; RtM204V

Indexed keywords

LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS MUTANT; VIRUS STRAIN;

EID: 84882838835     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.06.006     Document Type: Article

References (30)

1. Lok A.S., McMahon B.J. Chronic hepatitis B: update. Hepatology 2007, 45:507-539.
2. Ghany M., Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007, 132:1574-1585.
3. European Association For The Study Of The Liver EASL clinical practice guidelines. Management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
4. Carosi G., Rizzetto M., Alberti A., Cariti G., Colombo M., Craxì A., et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011, 43:259-265.
5. Lok A.S., Zoulim F., Locarnini S., Ghany M.G., Pawlotsky J.M., Liaw Y.F., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46:254-265.
6. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608.
7. Ghany M.G., Doo E.C. Antiviral resistance and hepatitis B therapy. Hepatology 2009, 49:S174-S184.
8. Hayashi K., Katano Y., Ishigami M., Itoh A., Hirooka Y., Nakano I., et al. Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains. J Gastroenterol Hepatol 2010, 25:745-749.
9. Xu Z., Liu Y., Xu T., Chen L., Si L., Wang Y., et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J Clin Virol 2010, 48:270-274.
10. Coppola N., Pisapia R., Tonziello G., Martini S., Imparato M., Piai G., et al. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. Antivir Ther 2008, 13:307-318.
11. Sagnelli E., Imparato M., Coppola N., Pisapia R., Sagnelli C., Messina V., et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven hepatitis C: a multicenter study. J Med Virol 2008, 80:1547-1553.
12. Sagnelli E., Coppola N., Pisaturo M., Masiello A., Tonziello G., Sagnelli C., et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009, 49:1090-1097.
13. Coppola N., Tonziello G., Pisaturo M., Messina V., Guastafierro S., Fiore M., et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011, 83:1909-1916.
14. Coppola N., Masiello A., Tonziello G., Pisapia R., Pisaturo M., Sagnelli C., et al. Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. J Viral Hepat 2010, 17:493-500.
15. Nafa S., Ahmed S., Tavan D., Pichoud C., Berby F., Stuyver L., et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000, 32:1078-1088.
16. Moriconi F., Cavallone D., Stabile A., Colombatto P., Ciccorossi P., Cherubini B., et al. In house allele specific PCR method to study the kinetics of resistant variants during nucleos(t)ide analogs treatment in immunocompetent and immunocompromised patients. Dig Liv Dis 2012, 44S:S99.
17. Sagnelli E., Stroffolini T., Ascione A., Bonino F., Chiaramonte M., Colombo M., et al. The epidemiology of hepatitis delta infection in Italy. Promoting Group. J Hepatol 1992, 15:211-215.
18. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996, 93:4398-4402.
19. Gunther S., Fischer L., Pult I., Sterneck M., Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999, 52:25-137.
20. Girones R., Miller R.H. Mutation rate of the hepadnavirus genome. Virology 1989, 170:595-597.
21. Baxa D.M., Thekdi A.D., Golembieski A., Krishnan P.V., Sharif O., Kizy A., et al. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol 2013, 58:212-216.
22. Luo Q., Zhong Y., Yang Y., Xiong Q., Hu Z., Lu W., et al. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains. J Med Virol 2012, 84:1558-1561.
23. Mello F.C., Lago B.V., Lewis-Ximenez L.L., Fernandes C.A., Gomes S.A. Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol 2012, 6(12):96.
24. Kobayashi S., Ide T., Sata M. Detection of YMDD motif mutations in some lamivudine untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001, 34:584-586.
25. Huang Z.M., Huang Q.W., Qin Y.Q., He Y.Z., Qin H.J., Zhou Y.N., et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005, 11:867-870.
26. Pollicino T., Isgrò G., Di Stefano R., Ferraro D., Maimone S., Brancatelli S., et al. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antivir Ther 2009, 14:649-654.
27. Margeridon-Thermet S., Shulman N.S., Shahriar R., Liu T., Wang C., Holmes S.P., et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naïve patients. J Infect Dis 2009, 199:1275-1285.
28. Sayan M., Akhan S.C., Meric M. Naturally occurring aminoacid substitutions to nucleos(t)ide analogues in treatment naïve Turkish patients with chronic hepatitis B. J Viral Hepat 2010, 17:23-27.
29. Fung S., Wong F., Mazzulli T., Popovic V. Pre-existing antiviral-resistant mutation may be associated with primary non-response to lamivudine among treatment-naïve chronic hepatitis B patients. Hepatology 2009, 50:523A.
30. Mirandola S., Campagnolo D., Bortoletto G., Franceschini L., Marcolongo M., Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hep 2011, 18:e212-e216.